- The Wall Street Journal•1 hour ago
China’s drug regulator approved Bristol-Myers Squibb’s all-oral treatment for hepatitis C, which will be the first therapy of its kind for the liver disease to be sold in the country, giving the U.S. company ...
- Motley Fool•yesterday
Shares of Signet Jewelers Ltd. and Bristol-Myers Squibb have had a rough year. Has the market gone too far, or are these value stocks actually value traps?
- Thomson Reuters StreetEvents•yesterday
Q1 2017 Bristol-Myers Squibb Co Earnings Call
BMY : Summary for Bristol-Myers Squibb Company - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||55.37 - 56.33|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||19.47|
|Dividend & Yield||1.56 (2.78%)|
|1y Target Est||N/A|